INGELHEIM, Germany and ZURICH, Switzerland, November 04, 2025--Boehringer Ingelheim and CDR-Life, Inc. today announced a new ...
FDA feedback enables CervoMed to proceed with proposed endpoints, patient enrichment strategy, and other key aspects of Phase 3 trial design to support potential New Drug Application CervoMed is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback